C12N 2710/16711
Varicellovirus
Official title: Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
C12N2710/16711 (Varicellovirus) appears on 486 US grants and 411 published applications in this corpus.
Search patents in C12N- Granted patents
- 486
- Published applications
- 411
- Assignees
- 298
- Inventors
- 1,127
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 6 | 0 |
| 1978 | 3 | 0 |
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 2 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 3 | 0 |
| 1987 | 6 | 0 |
| 1988 | 5 | 0 |
| 1989 | 6 | 0 |
| 1990 | 2 | 0 |
| 1991 | 11 | 0 |
| 1992 | 8 | 0 |
| 1993 | 9 | 0 |
| 1994 | 10 | 0 |
| 1995 | 9 | 0 |
| 1996 | 12 | 0 |
| 1997 | 20 | 0 |
| 1998 | 44 | 0 |
| 1999 | 24 | 0 |
| 2000 | 20 | 0 |
| 2001 | 32 | 5 |
| 2002 | 14 | 13 |
| 2003 | 12 | 25 |
| 2004 | 13 | 15 |
| 2005 | 6 | 10 |
| 2006 | 8 | 13 |
| 2007 | 6 | 16 |
| 2008 | 6 | 18 |
| 2009 | 7 | 8 |
| 2010 | 8 | 15 |
| 2011 | 4 | 11 |
| 2012 | 1 | 9 |
| 2013 | 5 | 13 |
| 2014 | 11 | 20 |
| 2015 | 7 | 8 |
| 2016 | 9 | 25 |
| 2017 | 17 | 14 |
| 2018 | 12 | 18 |
| 2019 | 17 | 15 |
| 2020 | 12 | 18 |
| 2021 | 10 | 17 |
| 2022 | 13 | 25 |
| 2023 | 12 | 22 |
| 2024 | 8 | 19 |
| 2025 | 18 | 23 |
| 2026 | 10 | 16 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/16734Use of virus or viral component as vaccineIndexing code287
- C12N 2710/16722New viral proteins or individual genes, new structural or functional aspects ofIndexing code252
- C12N 2710/16741Use of virus, viral particle or viral elements as a vectorIndexing code82
- C12N 2710/16761Methods of inactivation or attenuationIndexing code60
- C12N 2710/16721Viruses as suchIndexing code25
- C12N 2710/16771Demonstrated in vivo effectIndexing code24
- C12N 2710/16751Methods of production or purification of viral materialIndexing code17
- C12N 2710/16732Use of virus as therapeutic agent, other than vaccineIndexing code11
Recent patents
- Method for production of Varicella Zoster Virus surface protein antigen29 Sep 2026US 12,747,427 B2The Green Cross Corporation
- Varicella zoster virus (VZV) vaccine12 May 2026US 12,622,960 B2ModernaTX, Inc.
- Pharmaceutical composition and use thereof12 May 2026US 12,622,962 B2Grand Theravac Life Sciences (Nanjing) Co., Ltd.
- Shingles vaccines comprising a TLR9 agonist10 Mar 2026US 12,569,553 B2Dynavax Technologies Corporation
- Recombinant nucleic acids containing alphaherpesvirus promoter sequences17 Feb 2026US 12,551,574 B2The Trustees of Princeton University
- Mutated fragment of vzv glycoprotein e1 Oct 2026US 2026/0295035 A1
- A Fusion Protein and a Particulate Antigen Containing the Same27 Aug 2026US 2026/0250328 A1Xiamen Innovax Biotech Co., Ltd.
- Fusion protein of ge and gi of varicella-zoster virus and use6 Aug 2026US 2026/0224694 A1
- Nucleic Acid Vaccines for Varicella-Zoster Virus (VZV)6 Aug 2026US 2026/0224695 A1Everest Medicines (Singapore) Pte. Ltd.
- Immunogenic compositions and methods of inducing an immune response against varicella zoster virus30 Jul 2026US 2026/0216319 A1Pfizer Inc.
Most cited
By later US patents
- Eukaryotic layered vector initiation systems204US 5,814,482 A1998
- Alphavirus vector constructs167US 5,843,723 AChiron Corporation · 1998
- Alphavirus structural protein expression cassettes152US 5,789,245 AChiron Corporation · 1998
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998